期刊
BIOMEDICINES
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10020398
关键词
Alzheimer's disease; schizophrenia; depression; major depressive disorder; drug design; muscarinic receptors; muscarinic agonist; muscarinic antagonist; positive allosteric modulator
资金
- NIMH [R01-107499]
This article discusses the significant role of the cholinergic system in CNS disorders and recent advances in drug design targeting mAChRs. Despite challenges, progress has been made in developing functionally selective orthosteric and allosteric ligands with limited side effects for the treatment of diseases like Alzheimer's and schizophrenia.
There is substantial evidence that cholinergic system function impairment plays a significant role in many central nervous system (CNS) disorders. During the past three decades, muscarinic receptors (mAChRs) have been implicated in various pathologies and have been prominent targets of drug-design efforts. However, due to the high sequence homology of the orthosteric binding site, many drug candidates resulted in limited clinical success. Although several advances in treating peripheral pathologies have been achieved, targeting CNS pathologies remains challenging for researchers. Nevertheless, significant progress has been made in recent years to develop functionally selective orthosteric and allosteric ligands targeting the mAChRs with limited side effect profiles. This review highlights past efforts and focuses on recent advances in drug design targeting these receptors for Alzheimer's disease (AD), schizophrenia (SZ), and depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据